๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanning
Clinical trial register · China

Clinical Trials in Nanning, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Nanning 7 Shenzhen 4 Guangzhou 4 Kunming 2 Shanghai 2
Narrow the registerReset
Recruitment status
Phase
Site location
Nanning7 Shenzhen4 Guangzhou4 Kunming2 Shanghai2
All 14 locations
Target enrolment
to

Trials with a site in Nanning

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
NCT06717932Beta-Thalassemia
CorrectSequence Therapeutics Co., Ltd
Observational
8
Nanning
2025-05-15
By invitation
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06685536Beta-Thalassemia
CorrectSequence Therapeutics Co., Ltd
Observational
5
Nanning
2025-01-18
Recruiting
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent ฮฒ-thalassemia
NCT06772766Beta-Thalassemia
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
40
Nanning, Haikou
2024-12-30
By invitation
CS-101 in Patients With ฮฒ-thalassemia
NCT06328764Beta-Thalassemia
CorrectSequence Therapeutics Co., Ltd
Phase EARLY_PHASE1
10
Nanning
2024-03-19
Active, closed
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent ฮฒ-Thalassemia
NCT05577312Beta-Thalassemia
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Active, closed
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (ฮฒ)-Thalassemia.
NCT05567458Beta-thalassemia
Bristol-Myers Squibb
Phase 2
94
Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou
2022-10-17
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia
NCT04143724Beta-Thalassemia
Celgene
Phase 2
99
Guangzhou, Shenzhen, Nanning, Chengdu
2019-11-07
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanning

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Nanning that also match the filters currently applied.

How many clinical trials are recruiting in Nanning?

2 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanning), 7 studies
PhaseStudiesRecruitingShare
Observational2028.6%
Phase 22128.6%
Phase 11114.3%
Phase 1/21014.3%
Phase EARLY_PHASE11014.3%

Most active sponsors

Lead sponsors with the most studies (Nanning)
Lead sponsorStudiesRecruiting
CorrectSequence Therapeutics Co., Ltd30
Bioray Laboratories10
Bristol-Myers Squibb10
Celgene11
Mabwell (Shanghai) Bioscience Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.